Free speech can wait?
Executive Summary
FDA should extend the timeline for responses to a request-for-comment on First Amendment issues, Pfizer and the Pharmaceutical Research & Manufacturers of America tells the agency. "As an institutional matter, Pfizer is committing substantial time and resources to reviewing and responding to the notice," the company said. "Pfizer intends to consult with various experts concerning many of these questions to prepare more fully informed comments." FDA asked for comments by July 30 on the legal basis for its promotional rules with another 45-days for rebuttals (1"The Pink Sheet" May 20, p. 14). PhRMA and Pfizer are asking for a 60-day extension, which would move the final deadline back until the week after Election Day...
You may also be interested in...
Free speech comment deadline extended
FDA grants 45-day extension for comments on First Amendment issues and agency regulation of commercial speech. Comments will be due Sept. 13, rebuttal comments Oct. 28. The extension comes "in response to several requests from the public," agency says. Pfizer and Pharmacia are among those who asked FDA for additional time; the companies requested a 60-day extension (1"The Pink Sheet" Jun. 24, In Brief). FDA solicits comments on free speech in July 3 Journal of the American Medical Association "News and Analysis" section...
FDA Seeks Comment On Ad Regs: Can Rx Be More Regulated Than OTCs?
FDA is requesting comment on the legal underpinnings for arguing that promotions of prescription drugs can be more tightly regulated than those for other products
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.